Influence of single-nucleotide polymorphisms on deferasirox Ctrough levels and effectiveness
The Pharmacogenomics Journal2014Vol. 15(3), pp. 263–271
Citations Over TimeTop 16% of 2014 papers
Related Papers
- → Deferasirox (Exjade®) for the Treatment of Iron Overload(2009)62 cited
- → A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major(2019)24 cited
- → Approaching low liver iron burden in chelated patients with non‐transfusion‐dependent thalassemia: the safety profile of deferasirox(2014)18 cited
- → COMPARISON OF DEFERASIROX AND DESFERRIOXAMINE AS IRON CHELATORS IN MULTI-TRANSFUSED PATIENTS OF Β-THALASSEMIA MAJOR(2023)1 cited